Life Molecular Imaging And SOFIE Announce Neuraceq® Availability In Houston
Life Molecular Imaging And SOFIE Announce Neuraceq® Availability In Houston. Life Molecular Imaging and SOFIE Biosciences, a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE’s radiopharmaceutical manufacturing site located in Houston, Texas. The first doses will be available on January 9th, 2023.
Neuraceq® is an FDA-approved imaging agent for the detection of beta-amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline. It is used in clinical routine and is also a powerful imaging biomarker for the appropriate characterisation of subjects enrolled in clinical trials to support drug development in neurodegenerative diseases.
“With the addition of Houston, TX to our distribution network, Life Molecular Imaging continues to expand the availability of Neuraceq®, an important diagnostic imaging tool for the detection of beta-amyloid plaques in the brain. We are truly excited about our continued collaboration with SOFIE to provide greater availability of our approved beta-amyloid tracer Neuraceq® to physicians and their patients, and to our pharma partners for routine clinical and research use,” said Ludger Dinkelborg, Ph.D., Managing Director at LMI.
Patrick Phelps, SOFIE president & CEO states, “After many years of hard work from numerous scientists and clinicians, the recent news in the treatment of Alzheimer’s disease seems extremely promising. SOFIE is committed to the further expansion and availability of LMI’s Neuraceq® PET diagnostic tracer throughout our national PET manufacturing and dispensing network.”
Life Molecular Imaging (LMI, formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. It is now part of the Alliance Medical Group (a member of the Life Healthcare Group) offering an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities.
Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 38 years’ experience in the South African private healthcare sector, and currently operates 66 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, and wellness, occupational health, primary health and emergency medical services. The Group owns Alliance Medical Group, the leading independent provider of medical imaging services (MRI, CT, and PET scans) within Europe, operating internationally across 10 countries.
